Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
Adagio Medical Announces Initiation and First Patient Enrollment in PARALELL Trial To Investigate Safety and Performance of CryoPulse™ Catheter System for Pulsed Field Ablation and Pulsed Field Cryoablation of Persistent Atrial Fibrillation
laragione.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laragione.eu Daily Mail and Mail on Sunday newspapers.
(1)
LAGUNA HILLS, Calif., July 7, 2021 /PRNewswire/ Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT.
The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, Associate Director, Cardiovascular Center Department of Cardiology, Electrophysiology Section at the Cardiovascular Center OLV Hospital, Aalst, Belgium. Procedural success was ascertained by the lack of the inducible arrhythmia after a set of ULTC lesions was delivered to isolate inferior-posterior ischemic scar in patient s left ventricle. No procedural complications were observed, and patient remained arrhythmia-free through the first 30 days of the follow-up.